Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...134135136137138139140141142143144...170171»
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Journal:  Bone cement leaking into iliac vein during artificial femoral head replacement: A case report. (Pubmed Central) -  Oct 25, 2019   
    2012;34:XXX-XXX) This case calls into the phenomenon of leakage of injected bone cement in femoral head replacement regardless of complete and nonfractured femur, which may be into the lower limb and pelvic veins, given that, dangerous consequences will not occur.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
    Journal:  Recommendations for the Use of Indirect and Direct Anticoagulants for Long-Term Prophylaxis after Venous Thromboembolism (Pubmed Central) -  Oct 24, 2019   
    If there is a high risk of recurrence with unchanged trigger factor (e.g. active malignancy, unambiguous antiphospholipid syndrome or deficiency of a clotting factor, such as Protein C, Protein S or antithrombin with a positive family history of venous thromboembolism, first occurrence of a pulmonary embolism, multiple recurrence of VTE) prolonged maintenance therapy is indicated, unless this is contraindicated by a very high risk of bleeding. For all patients with former VTE and whose anticoagulation phase has in principle been completed, prolonged prophylaxis can be continued, as these patients too are at increased risk of VTE.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg., warfarin / Generic Mfg.
    The Use of Direct Oral Anticoagulants in Membranous Nephropathy () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5479;    
    In those considered high risk, options include warfarin, heparin or aspirin...There were 3 thromboembolic events in 3 patients; all events occurred on rivaroxaban and in PLA2Rab positive MN...Conclusion Our experience is that DOACs are safe and effective in patients with MN and offer a viable anti-coagulant alternative. Table 1: Cohort demographics
  • ||||||||||  Fabrazyme (agalsidase beta) / Sanofi
    Enzyme Replacement Therapy and Fabry Nephropathy () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5429;    
    Currently, Cr is 0.8 mg/dL and proteinuria 0.17 g/day. Discussion This 6-year study has documented the effectiveness of agalsidase beta in patients with FN, despite delayed initiation of ERT.
  • ||||||||||  Retrospective data, Journal:  Differences In Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis. (Pubmed Central) -  Oct 22, 2019   
    Apixaban had the highest probability of being the safest option with regard to the risk of MGI bleeding (89.1%), followed by edoxaban (77.4%), conventional therapy (51.4%), dabigatran etexilate (23.8%) and rivaroxaban (8.3%). The risk of GI bleeding significantly varies among different NOAC regimens, and evidence shows that apixaban and edoxaban had the most favorable MGI bleeding safety profile, while rivaroxaban and dabigatran etexilate were the least safe.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic Mfg., Eliquis (apixaban) / BMS
    Journal:  Ruling out lupus anticoagulants with mixing test-specific cutoff assessment and the index of circulating anticoagulant. (Pubmed Central) -  Oct 19, 2019   
    The data indicate that MTC has a tendency to generate not-corrected mixing tests in factor-deficient, warfarin, and other inhibitor samples, while ICA exhibited higher specificity. When we perform the mixing test and interpret the data, it is important to understand the characteristics of the indexes for maximizing the diagnostic potential of mixing test.
  • ||||||||||  Review, Journal:  Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update. (Pubmed Central) -  Oct 18, 2019   
    A new generation of anticoagulants, the DOACs, and their reversal agents, are gaining prominence in clinical practice, having demonstrated superior efficacy and safety profiles. They are poised to replace traditional anticoagulants including warfarin.
  • ||||||||||  Eliquis (apixaban) / BMS
    Journal, Adverse events:  TO BLEED OR NOT TO BLEED: THAT IS THE QUESTION. THE SIDE EFFECTS OF APIXABAN. (Pubmed Central) -  Oct 18, 2019   
    All of them are prescribed to patients with non valvular atrial fibrillation or venous thromboembolism, to replace warfarin, because of the lower probability of bleeding, however they can cause bleeding by themselves...Many physicians still have limited experience with new oral anticoagulants and about bleeding risks managment. We reviewed the available literature on extracranial and intracranial bleeding concerning apixaban.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. (Pubmed Central) -  Oct 18, 2019   
    However, the ABCB1 1236 C > T-2677G > T-3435C > T and 1199 G > A SNPs had no significant influence on the intracellular accumulation of rivaroxaban when compared to the wild-type protein. These results suggest that the ABCB1 coding SNPs investigated in the present study are unlikely to contribute to the inter-individual variability in rivaroxaban plasma concentrations.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Trial completion date:  COBRRA: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (clinicaltrials.gov) -  Oct 17, 2019   
    P4,  N=2760, Recruiting, 
    Although these results are descriptive and limited in number of patients, we believe this is ample evidence that DOACs are relatively safe and efficacious in treatment of patients with AF and concomitant LAA thrombus. Trial completion date: May 2022 --> Dec 2022
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Ovarian vein thrombosis in a gestational trophoblastic neoplasia patient () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1718;    
    OVT with only acute abdominal pain is unlikely to be suspected in GTN patients, and thus is found incidentally on CT for metastatic evaluation. Therefore, it is important to have a CT scan if GTN patients have symptoms such as abdominal pain or dyspnea.
  • ||||||||||  Clinical, Retrospective data, Journal:  Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants. (Pubmed Central) -  Oct 16, 2019   
    Conclusions- Because NOAC use is associated with higher ischemic stroke risk together with a lower risk of hemorrhages than warfarin use, it can be concluded that patients on warfarin are more strongly anticoagulated. The observed effect could be a secondary consequence of dosage control or alternatively a result of different anticoagulant effects among the different medications.
  • ||||||||||  Clinical, Journal:  Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease. (Pubmed Central) -  Oct 16, 2019   
    For mild-AD patients living in the community, edoxaban increased lifetime costs by $6603 and increased QALYs by 0.076 compared to warfarin, yielding an incremental cost-effectiveness ratio of $86 882/QALY gained...For patients living in a long-term care facility with mild AD, the DOAC with the lowest incremental cost-effectiveness ratio (rivaroxaban) costs $150 169 per QALY gained; for patients with more severe AD, the incremental cost-effectiveness ratios were higher...Even though patients with moderate and severe AD living in the community and patients with any stage of AD living in a long-term care setting may obtain positive clinical benefits from anticoagulation treatment, DOACs are not cost-effective compared with warfarin for these populations. Compared to aspirin, no oral anticoagulation (warfarin or any DOAC) is cost effective in patients with AF and AD.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, aspirin / Generic mfg.
    New P2 trial:  ARIVA: Aspirin (clinicaltrials.gov) -  Oct 15, 2019   
    P2,  N=316, Not yet recruiting, 
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis (clinicaltrials.gov) -  Oct 15, 2019   
    P=N/A,  N=12, Active, not recruiting, 
    The RI constitutes a useful, additional tool to facilitate clinicians in choosing DOACs or warfarin in particular category of AF patients. Recruiting --> Active, not recruiting | N=56 --> 12 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020